Clinical Investigation Center

Dogs with hemangiosarcoma - new chemo agent trial

Dog - white shepherd face
Current Status:
Open and enrolling
Principal Investigator: Antonella Borgatti, DVM, MS, DACVIM (Oncology), DECVIM-CA
Contacts: Dr. Borgatti at the Oncology Service, 612-626-8387
Amber Winter, Research Technician Specialist: alwinter@umn.edu, 612-624-1352

We are evaluating a new chemotherapeutic agent for dogs with residual disease of measurable hemangiosarcoma. The new agent is approved for the treatment of patients with metastatic breast cancer and liposarcoma in humans and has shown anticancer effects in healthy animals in the laboratory. This study will measure response to therapy by evaluating changes seen in measurable lesions. The study is also a dose-finding trial to determine the safest dose of the new chemotherapeutic agent which is still effective.

Eligible dogs

  • histopathological confirmation of hemangiosarcoma (HSA). For dogs with splenic HSA, splenectomy will be necessary prior to enrolling. Visual tumors will be 1 cm or greater to qualify.
  • residual disease seen on imaging, CT, radiographs or caliper measurement
  • 1 year or older
  • at least 10 kg (22 lbs) (Dogs less than 10 kg will be considered on a case by case basis)
  • have a performance score of 0-1 (normal activity level)
  • systemically healthy other than having HSA
  • have not had previous treatment for HSA beside surgical removal
  • other restrictions apply, call for details

Study summary

  • Screening visit - blood and urine testing, chest radiographs, abdominal ultrasound and possible CT
  • If residual disease seen, eligible to enroll
  • 1st cycle of treatment: Treatment days 1 and 7, overnight stay in ICU for monitoring
  • 2nd cycle: Treatment days 21 and 30 (as above, note if dose increased, will stay overnight)
  • 3rd cycle: Treatment days 42 and 50 (as above, note if dose increased, will stay overnight))
  • Each cycle could be the same dose, an increased dose or a decreased dose. The plan will be discussed with owners prior to each treatment.
  • Primary endpoint Day 63: restaging by chest radiographs, abdominal ultrasound (with or without sampling of abdominal fluid), CT (external-only HSA may not receive CT)
  • Monthly restaging visits for exam, samples for clinical pathology, chest radiographs and abdominal ultrasound
  • Final visit Day 174 (25th week) with same as monthly staging visits

Costs of the study

Owners will be responsible for the costs associated with diagnosis of hemangiosarcoma and splenectomy. The study covers the costs of the screening and visits described above. 

For more information, please contact Amber Winter (see above).